(Q33354953)

26 July 2017

title

Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2. (English)

1 reference

26 July 2017

0 references

12

Junzo Kigawa

1 reference

26 July 2017

1

Hiroaki Itamochi

1 reference

26 July 2017

4

Tetsuro Oishi

1 reference

26 July 2017

6

Shinya Sato

1 reference

26 July 2017

5

Muneaki Shimada

1 reference

26 July 2017

13

Tasuku Harada

1 reference

26 July 2017

11

Naoki Terakawa

1 reference

26 July 2017

2

Misaki Kato

1 reference

26 July 2017

3

Mayumi Nishimura

1 reference

26 July 2017

10

Akiko Kudoh

1 reference

26 July 2017

Jun Naniwa

7

1 reference

26 July 2017

Seiya Sato

series ordinal

8

1 reference

26 July 2017

Michiko Nonaka

series ordinal

9

1 reference

26 July 2017

publication date

30 December 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

25

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

111-115

1 reference

describes a project that uses

26 July 2017

TU-OS-4

0 references

cites work

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13577-012-0048-1

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-012-0048-1

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-012-0048-1

Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-012-0048-1

Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-012-0048-1

Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-012-0048-1

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-012-0048-1

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-012-0048-1

Ovarian cancer: strategies for overcoming resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-012-0048-1

Novel agents on the horizon for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-012-0048-1

ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23274876

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23274876

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23274876

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13577-012-0048-1

1 reference

Dimensions Publication ID

26 July 2017

1004735991

0 references

1 reference